Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial save search
ALX Oncology Reports Encouraging Clinical Data of Evorpacept in Combination with Standard-of-Care in an Ongoing Phase 1/2 Clinical Trial in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (“R/R B-NHL”)
Published: 2024-04-09 (Crawled : 22:00) - globenewswire.com
ALXO M | $15.6 -0.89% -0.9% 480K
|
Commercial Services
|
| O: -2.59%
H: 1.75%
C: 0.25%
ongoing trial
Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Published: 2024-04-09 (Crawled : 20:00) - globenewswire.com
CRVS | $1.4 -0.71% -0.71% 59K
|
Health Technology
|
| O: 2.45%
H: 0.0%
C: -9.58%
dermatitis pharmaceuticals for trial
DOJ Senior Trial Counsel Amy Kossak Joins Ropes & Gray's Government Enforcement Team
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
trial
Fusion Pharmaceuticals Announces Presentation of Interim Data from the Phase 2 TATCIST Clinical Trial Evaluating FPI-2265 at the AACR Annual Meeting 2024
Published: 2024-04-09 (Crawled : 20:00) - prnewswire.com
FUSN | $21.26 0.05% 0.05% 440K
|
Health Technology
|
| O: -0.19%
H: 0.28%
C: 0.09%
fpi-2265 presentation pharmaceuticals meeting trial
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
RAPT | $7.96 0.38% 0.38% 790K
|
Health Technology
|
| O: 0.0%
H: 3.37%
C: 1.44%
cancer immunotherapy trial therapeutics results
Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen
Published: 2024-04-09 (Crawled : 16:00) - globenewswire.com
ATOS | $1.37 -3.52% -3.65% 1.2M
|
Health Technology
|
| O: 0.57%
H: 11.65%
C: 4.55%
disease control treatment trial therapeutics
NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease
Published: 2024-04-09 (Crawled : 12:00) - globenewswire.com
NAMS | $19.98 2.78% 2.7% 140K
|
n/a
|
| O: -6.3%
H: 2.72%
C: -2.67%
pharma disease global trial cardiovascular
Seres Therapeutics Announces Completion of Patient Enrollment for SER-155 Phase 1B Cohort 2 Clinical Trial in Allogenic HSCT
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
MCRB | $0.5671 -2.93% -3.02% 3.7M
|
Health Technology
|
| O: -2.31%
H: 3.86%
C: -1.47%
ser-155 for trial therapeutics
GammaTile® Marks Milestone: 100th Patient Enrolled in Groundbreaking ROADS Phase 3 Clinical Trial for Newly Diagnosed Metastatic Brain Tumors
Published: 2024-04-09 (Crawled : 12:00) - biospace.com/
FNCTF | News | $11.0354 -20.84% 320
|
Communications
|
| O: 0.17%
H: 0.0%
C: -0.43%
gammatile tumors for trial
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS
Published: 2024-04-09 (Crawled : 10:00) - prnewswire.com
BCLI A | $0.5384 4.69% 4.48% 1M
|
Health Technology
|
| O: 10.45%
H: 0.0%
C: 0.0%
fda als cell for trial therapeutics agreement
Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Published: 2024-04-08 (Crawled : 20:00) - globenewswire.com
KA A | $0.5196 6.89% 6.45% 480K
|
Manufacturing
|
| O: -12.68%
H: 3.59%
C: -8.72%
vista-101 ongoing trial response
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 2 d | $3.08 1.99% 1.95% 230K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research
Published: 2024-04-08 (Crawled : 12:30) - globenewswire.com
ENTX | $1.985 -11.38% -12.85% 300K
|
Health Technology
|
| O: 2.3%
H: 1.25%
C: -2.5%
eb613 publication research bone trial
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
IGXT | $0.17 -19.77% 73K
|
Manufacturing
|
| O: -5.24%
H: 8.65%
C: 8.65%
versafilm first disease montelukast parkinson’s trial
Corcept Completes Enrollment in Pivotal Phase 3 Rosella Trial of Relacorilant in Patients With Platinum-Resistant Ovarian Cancer
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
CORT | $22.97 1.37% 1.35% 920K
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: -4.98%
cancer trial
BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
BRTX | $1.39 -3.47% -3.6% 160K
|
Professional, Scientific, and T...
|
| O: -1.5%
H: 0.0%
C: -2.29%
brtx-100 disease trial
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.5 -1.75% -1.78% 590K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $20.82 1.61% 1.59% 850K
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -1.34%
gment-101 positive leukemia trial
Ocugen, Inc. Announces U.S. FDA Clearance of IND Amendment to Initiate OCU400 Phase 3 Clinical Trial — First Gene Therapy to Enter Phase 3 with a Broad Retinitis Pigmentosa Indication
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.315 -0.38% -0.38% 6.5M
|
Health Technology
|
| O: 26.42%
H: 3.48%
C: -6.47%
ocu400 fda first clearance trial therapy
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS | $11.78 0.0% 69K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.